Taken together, these results demonstrate that, compared to WT-MSCs, CXCR4-IL10-MSCs are characterized by an enhanced therapeutic efficacy to control the clinical signs of a humanized mouse model of GvHD. This evidence concerns the gene IL10 and graft versus host disease.